

Data Set Name: alldata.sas7bdat

Num	Variable	Type	Len	Label
1	SUBJECT_ID	Char	9	Subject ID
2	REDCAP_REPEAT_INSTANCE	Num	8	Repeat Instance
3	REDCAP_REPEAT_INSTRUMENT	Char	500	Repeat Instrument
4	RAND_TRT	Num	8	
5	IE_VERSION	Char	500	IE form version
6	IE_IOK	Num	8	Did the patient meet all inclusion criteria? Age_18 years Currently hospitalized or in an emergency department with anticipated hospitalization. Symptoms of acute respiratory infection, defined as one or more of the following: cough fever (> 37.5° C / 9
7	IE_IOK_V2	Num	8	Did the patient meet all inclusion criteria?Age_18 yearsCurrently hospitalized or in an emergency department with anticipated hospitalization.Symptoms of acute respiratory infection, defined as one or more of the following: coughfever (> 37.5° C / 99.5° F
8	IE_ARISYMPOMS__COU	Num	8	Which symptoms of acute respiratory infection does the patient present? (choice=Cough)
9	IE_ARISYMPOMS__FEV	Num	8	Which symptoms of acute respiratory infection does the patient present? (choice=Fever (> 37.5° C / 99.5° F))
10	IE_ARISYMPOMS__SOB	Num	8	Which symptoms of acute respiratory infection does the patient present? (choice=Shortness of breath)
11	IE_ARISYMPOMS__ST	Num	8	Which symptoms of acute respiratory infection does the patient present? (choice=Sore throat)
12	IE_LABSTATUS	Num	8	Specify the laboratory confirmation status:
13	IE_EPRIS	Num	8	Prisoner
14	IE_EPREG	Num	8	Pregnant
15	IE_EBREAST	Num	8	Breast feeding
16	IE_EARI	Num	8	Symptoms of acute respiratory infection for >10 days before randomization
17	IE_ELATE	Num	8	More than 48 hours from hospitalization
18	IE_ESEIZURE	Num	8	Seizure disorder
19	IE_EPORPHYRIA	Num	8	Porphyria cutanea tarda
20	IE_ELONGQT	Num	8	Diagnosis of Long QT syndrome
21	IE_EQTC500	Num	8	QTc >500 ms on electrocardiogram within 72 hours prior to randomization
22	IE_EALLERGY	Num	8	Known allergy to hydroxychloroquine, chloroquine, or amodiaquine
23	IE_ECONTRA	Num	8	Receipt in the 12 hours prior to randomization, or planned administration during the 5-day study period, of a contraindicated medication that treating clinicians feel cannot be substituted (any of the following): Amiodarone Cimetidine Dofetilide Phenobarb
24	IE_ECHLOR	Num	8	Receipt of >1 dose of hydroxychloroquine or chloroquine in the 10 days prior to randomization
25	IE_ENPO	Num	8	Inability to receive enteral medications
26	IE_ENOCONTACT	Num	8	Refusal or Inability to be contacted on Day 15 for clinical outcome assessment if discharged prior to Day 15
27	IE_PREVENROLL	Num	8	Previous enrollment in this trial

Num	Variable	Type	Len	Label
28	IE_EQUIPOISE	Num	8	The treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient
29	IE_NENE	Num	8	Not excluded but not enrolled
30	IE_NENESPEC	Char	5000	Please explain why the patient was not enrolled:
31	IE_ELIGIBLE	Num	8	Patient is eligible (1=yes, 0=no)
32	IE_APPROVED	Num	8	Did the treating clinicians provide permission to approach patient/LAR for informed consent discussion
33	IE_ENROLLED	Num	8	Was the patient enrolled?
34	IE_NOTENROLLEDREAS	Num	8	Reason not enrolled?
35	IE_NOTENROLLEDREAS_OTHER	Char	5000	If Other please describe:
36	CONS_CERTIFY	Num	8	Before randomization, the enrolling investigator must certify that that all of the following are true: Patient met all inclusion criteria Patient met no exclusion criteria Study Informed Consent Document/Form (ICD/ICF) were explained and reviewed with the
37	RAND_DT	Num	8	Randomization day
38	RAND_TM	Num	8	Randomization time
39	BL_AGE	Num	8	Age (patient must be at least 18 years of age)
40	BL_SEX	Num	8	Sex
41	BL_ETHNIC	Num	8	Ethnicity
42	BL_RACE__1	Num	8	Race (Check all that apply) (choice=Black or African American)
43	BL_RACE__OTHCAT	Num	8	Race (Check all that apply) (choice=American Indian or Alaska Native/Asian/Native Hawaiian or Other Pacific Islander)
44	BL_RACE__5	Num	8	Race (Check all that apply) (choice=White or Caucasian)
45	BL_RACE__6	Num	8	Race (Check all that apply) (choice=Other)
46	BL_HEIGHT	Num	8	Height (cm)
47	BL_WEIGHT	Num	8	Weight (kg)
48	BL_SYMPTOMDT	Num	8	Day of symptom onset
49	BL_HOSPADMDT	Num	8	Day of presentation to the study hospital
50	BL_HOSPADMTM	Num	8	Time of presentation to the study hospital
51	BL_PREHOSP	Num	8	Source of presentation to study hospital (select one)
52	BL_RANDLOC	Num	8	Location at randomization
53	BL_EKGQTC	Num	8	What was the QTc on the EKG prior to randomization? (ms)
54	BL_EKGDY	Num	8	What was the day of the EKG prior to randomization?
55	BL_EKGTM	Num	8	What was the time of the EKG prior to randomization?
56	CHARL_LEUK	Num	8	Leukemia (AML, CML, ALL, multiple myeloma)
57	CHARL_LYMPH	Num	8	Malignant lymphoma
58	CHARL_HEMIPLEGIA	Num	8	Hemiplegia
59	CHARL_CEREBVASC	Num	8	Cerebrovascular disease
60	CHARL_MYOINFARC	Num	8	A prior myocardial infarction
61	CHARL_CONGHEART	Num	8	Congestive heart failure
62	CHARL_PERIVASC	Num	8	Peripheral vascular disease

Num	Variable	Type	Len	Label
63	CHARL_DEMENTIA	Num	8	Dementia
64	CHARL_COPD	Num	8	COPD
65	CHARL_ASTHMA	Num	8	Asthma
66	CHART_OXYGEN	Num	8	Chronic receipt of supplemental oxygen prior to current illness Supplemental oxygen is defined as oxygen administered by nasal cannula, face mask, high-flow nasal cannula, non-invasive ventilation, or invasive ventilation. Positive airway pressure (CPAP o
67	CHARL_CONTIS	Num	8	Connective tissue disease
68	CHARL_ULCER	Num	8	Peptic ulcer disease
69	CHARL_HYPERTENSION	Num	8	History of hypertension
70	CHARL_CAD	Num	8	Coronary artery disease
71	CHARL_FATAL	Num	8	Rapidly fatal disease
72	CHARL_TUMOR	Num	8	Solid tumor
73	CHARL_LIVER	Num	8	Liver disease
74	CHARL_DIABETES	Num	8	Diabetes mellitus (DM)
75	CHARL_KIDNEY	Num	8	Moderate to severe kidney disease
76	RXHX_CORTICO	Num	8	Does the patient take corticosteroids as a home medication?
77	RXHX_ACE	Num	8	Does the patient take ACE inhibitors as a home medication?
78	RXHX_ARB	Num	8	Does the patient take angiotensin receptor blockers as a home medication?
79	RXHX_NSAIDS	Num	8	Does the patient regularly take non-steroidal anti-inflammatory drugs as a home medication?
80	VIT_HRH_1	Num	8	Highest heart rate, bpm
81	VIT_SPBL_1	Num	8	Lowest systolic blood pressure, mm Hg
82	VIT_VASOP_1	Num	8	Receipt of vasopressors
83	VIT_RRH_1	Num	8	Highest respiratory rate, breaths per minute
84	VIT_SPO2L_1	Num	8	Lowest SpO2
85	VIT_FIO2H_1	Num	8	Highest FiO2For patients on nasal cannula, use estimation that $FIO_2 = 0.21 + 0.03*(LPM \text{ of NC O}_2)$
86	VIT_RESPSUP_1	Num	8	Respiratory support at enrollment (select one)
87	SOFA_PAO2L_1	Num	8	Lowest PaO2
88	SOFA_PAO2LFIO2_1	Num	8	Value for FiO2 at the time of lowest PaO2For patients on nasal cannula, use estimation that $FIO_2 = 0.21 + 0.03*(LPM \text{ of NC O}_2)$
89	SOFA_SPO2L_1	Num	8	Lowest SpO2
90	SOFA_SPO2LFIO2_1	Num	8	Value for FiO2 at the time of lowest SpO2For patients on nasal cannula, use estimation that $FIO_2 = 0.21 + 0.03*(LPM \text{ of NC O}_2)$
91	SOFA_PLATL_1	Num	8	Lowest platelet count, per mm3 (in thousands)
92	SOFA_BILIH_1	Num	8	Highest bilirubin, mg/dL
93	SOFA_GCS_1	Num	8	Lowest Glasgow Coma Scale score
94	SOFA_MAPL_1	Num	8	Lowest mean arterial pressure, mmHg
95	SOFA_VASOYN_1	Num	8	Receipt of vasopressors

Num	Variable	Type	Len	Label
96	SOFA_VASO_1__DOBUT	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Dobutamine)
97	SOFA_VASO_1__DOPA	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Dopamine)
98	SOFA_VASO_1__EPI	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Epinephrine)
99	SOFA_VASO_1__NEOSYN	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Neosynephrine)
100	SOFA_VASO_1__NOREPI	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Norepinephrine)
101	SOFA_VASO_1__VASOP	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Vasopressin)
102	SOFA_DOBUT_1	Num	8	Dobutamine dose: (mcg/kg/min)
103	SOFA_DOPA_1	Num	8	Dopamine dose: (mcg/kg/min)
104	SOFA_EPI_1	Num	8	Epinephrine dose: (mcg/kg/min)
105	SOFA_NOREPI_1	Num	8	Norepinephrine dose: (mcg/kg/min)
106	SOFA_NEOSYN_1	Num	8	Neosynephrine dose: (mcg/kg/min)
107	SOFA_VASOP_1	Num	8	Vasopressin dose: (mcg/kg/min)
108	SOFA_CREATH_1	Num	8	Highest creatinine, mg/dL
109	SOFA_UOUT_1	Num	8	Urine output (estimated)
110	SOFA_INRH_1	Num	8	Highest international normalized ratio (INR)
111	LABS_YN_1	Num	8	Were the daily labs available for this study day? (Day 1)
112	LABS_NOREAS_1	Char	5000	If no, why not? (Day 1)
113	LABS_WBCH_1	Num	8	Highest white blood cell count (/mm ³) (Day 1)
114	LABS_WBCL_1	Num	8	Lowest white blood cell count (/mm ³) (Day 1)
115	LABS_HEMOL_1	Num	8	Lowest hemoglobin (g/dl) (Day 1)
116	LABS_SODIUMH_1	Num	8	Highest sodium (mEq/L) (Day 1)
117	LABS_SODIUML_1	Num	8	Lowest sodium (mEq/L) (Day 1)
118	LABS_POTASSIUMH_1	Num	8	Highest potassium (mEq/L) (Day 1)
119	LABS_POTASSIUML_1	Num	8	Lowest potassium (mEq/L) (Day 1)
120	LABS_CHLORIDEH_1	Num	8	Highest chloride (mEq/L) (Day 1)
121	LABS_BICARBONATEH_1	Num	8	Highest bicarbonate (mEq/L) (Day 1)
122	LABS_BICARBONATEL_1	Num	8	Lowest bicarbonate (mEq/L) (Day 1)
123	LABS_BUNH_1	Num	8	Highest BUN - Blood Urea Nitrogen (mg/dL) (Day 1)
124	LABS_TROPH_1	Num	8	Highest troponin (mg/dL) (Day 1)
125	LABS_ASTH_1	Num	8	Highest AST - Aspartate aminotransferase (units per liter) (Day 1)
126	LABS_ALTH_1	Num	8	Highest ALT - Alanine aminotransferase (units per liter) (Day 1)
127	LABS_ALPH_1	Num	8	Highest ALP - Alkaline Phosphatase (IU/L) (Day 1)
128	LABS_ALBUMINL_1	Num	8	Lowest albumin (g/dL) (Day 1)
129	LABS_PTH_1	Num	8	Highest PTT - Partial Thromboplastin Time (seconds) (Day 1)
130	PRMED_CHLOR	Num	8	Chloroquine (up to randomization)

Num	Variable	Type	Len	Label
131	PRMED_HYDROXYCHLOR	Num	8	Hydroxychloroquine (up to randomization)
132	PRMED_REMDESIVIR	Num	8	Remdesivir (up to randomization)
133	PRMED_LOPINAVIR	Num	8	Lopinavir/ritonavir (up to randomization)
134	PRMED_CORTICOSTER	Num	8	Corticosteroids (up to randomization)
135	PRMED_TOCILIZUMAB	Num	8	Tocilizumab (up to randomization)
136	PRMED_SARILUMAB	Num	8	Sarilumab (up to randomization)
137	PRMED_INTERFERON	Num	8	Interferon _ (up to randomization)
138	PRMED_AZITHRO	Num	8	Azithromycin (up to randomization)
139	PRMED_OTHER	Num	8	Other medication(s) between hospital admission and randomization felt to be relevant to trial?
140	PRMED_OTHERSPEC	Char	5000	If other medication(s), which medication(s)?
141	PRTRT_CONPLAS	Num	8	Convalescent plasma (up to randomization)?
142	PRTRT_IMMGLOB	Num	8	SARS-CoV-2 hyperimmune globulin (up to randomization)?
143	PRTRT_MONOCANTI	Num	8	Monoclonal antibodies (up to randomization)?
144	COVID_OOSCALE_1	Num	8	COVID Ordinal Outcomes Scale at randomization
145	DOSE_YN_1	Num	8	Was dose 1 of study medication given?Dose 1 is scheduled to be given 4 hours after randomization
146	DOSE_DT_1	Num	8	Day dose 1 administered
147	DOSE_TM_1	Num	8	Time dose 1 administered
148	DOSE_INT_1	Num	8	Hours since randomization
149	DOSE_NOTADM_1	Num	8	Reason study drug dose 1 not administered
150	DOSE_NOTADMOTH_1	Char	5000	Other reason study drug dose 1 not administered
151	DOSE_NOTADMSPEC_1	Char	5000	Please give detailed description of why study drug dose 1 was not administered
152	DOSE_YN_2	Num	8	Was dose 2 of study medication given?Dose 2 is scheduled to be given between 8 and 16 hours after prior scheduled dose
153	DOSE_DT_2	Num	8	Day dose 2 administered
154	DOSE_TM_2	Num	8	Time dose 2 administered
155	DOSE_INT_2	Num	8	Hours since last dose:
156	DOSE_NOTADM_2	Num	8	Reason study drug dose 2 not administered
157	DOSE_NOTADMOTH_2	Char	5000	Other reason study drug dose 2 not administered
158	DOSE_NOTADMSPEC_2	Char	5000	Please give detailed description of why study drug dose 2 was not administered
159	DOSE_YN_3	Num	8	Was dose 3 of study medication given?Dose 3 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
160	DOSE_DT_3	Num	8	Day dose 3 administered
161	DOSE_TM_3	Num	8	Time dose 3 administered
162	DOSE_INT_3	Num	8	Hours since last dose:
163	DOSE_NOTADM_3	Num	8	Reason study drug dose 3 not administered
164	DOSE_NOTADMOTH_3	Char	5000	Other reason study drug dose 3 not administered
165	DOSE_NOTADMSPEC_3	Char	5000	Please give detailed description of why study drug dose 3 was not administered

Num	Variable	Type	Len	Label
166	DOSE_YN_4	Num	8	Was dose 4 of study medication given?Dose 4 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
167	DOSE_DT_4	Num	8	Day dose 4 administered
168	DOSE_TM_4	Num	8	Time dose 4 administered
169	DOSE_INT_4	Num	8	Hours since last dose:
170	DOSE_NOTADM_4	Num	8	Reason study drug dose 4 not administered
171	DOSE_NOTADMOTH_4	Char	5000	Other reason study drug dose 4 not administered
172	DOSE_NOTADMSPEC_4	Char	5000	Please give detailed description of why study drug dose 4 was not administered
173	DOSE_YN_5	Num	8	Was dose 5 of study medication given?Dose 5 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
174	DOSE_DT_5	Num	8	Day dose 5 administered
175	DOSE_TM_5	Num	8	Time dose 5 administered
176	DOSE_INT_5	Num	8	Hours since last dose:
177	DOSE_NOTADM_5	Num	8	Reason study drug dose 5 not administered
178	DOSE_NOTADMOTH_5	Char	5000	Other reason study drug dose 5 not administered
179	DOSE_NOTADMSPEC_5	Char	5000	Please give detailed description of why study drug dose 5 was not administered
180	DOSE_YN_6	Num	8	Was dose 6 of study medication given?Dose 6 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
181	DOSE_DT_6	Num	8	Day dose 6 administered
182	DOSE_TM_6	Num	8	Time dose 6 administered
183	DOSE_INT_6	Num	8	Hours since last dose:
184	DOSE_NOTADM_6	Num	8	Reason study drug dose 6 not administered
185	DOSE_NOTADMOTH_6	Char	5000	Other reason study drug dose 6 not administered
186	DOSE_NOTADMSPEC_6	Char	5000	Please give detailed description of why study drug dose 6 was not administered
187	DOSE_YN_7	Num	8	Was dose 7 of study medication given?Dose 7 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
188	DOSE_DT_7	Num	8	Day dose 7 administered
189	DOSE_TM_7	Num	8	Time dose 7 administered
190	DOSE_INT_7	Num	8	Hours since last dose:
191	DOSE_NOTADM_7	Num	8	Reason study drug dose 7 not administered
192	DOSE_NOTADMOTH_7	Char	5000	Other reason study drug dose 7 not administered
193	DOSE_NOTADMSPEC_7	Char	5000	Please give detailed description of why study drug dose 7 was not administered
194	DOSE_YN_8	Num	8	Was dose 8 of study medication given?Dose 8 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
195	DOSE_DT_8	Num	8	Day dose 8 administered
196	DOSE_TM_8	Num	8	Time dose 8 administered
197	DOSE_INT_8	Num	8	Hours since last dose:
198	DOSE_NOTADM_8	Num	8	Reason study drug dose 8 not administered
199	DOSE_NOTADMOTH_8	Char	5000	Other reason study drug dose 8 not administered
200	DOSE_NOTADMSPEC_8	Char	5000	Please give detailed description of why study drug dose 8 was not administered

Num	Variable	Type	Len	Label
201	DOSE_YN_9	Num	8	Was dose 9 of study medication given?Dose 9 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
202	DOSE_DT_9	Num	8	Day dose 9 administered
203	DOSE_TM_9	Num	8	Time dose 9 administered
204	DOSE_INT_9	Num	8	Hours since last dose:
205	DOSE_NOTADM_9	Num	8	Reason study drug dose 9 not administered
206	DOSE_NOTADMOTH_9	Char	5000	Other reason study drug dose 9 not administered
207	DOSE_NOTADMSPEC_9	Char	5000	Please give detailed description of why study drug dose 9 was not administered
208	DOSE_YN_10	Num	8	Was dose 10 of study medication given?Dose 10 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
209	DOSE_DT_10	Num	8	Day dose 10 administered
210	DOSE_TM_10	Num	8	Time dose 10 administered
211	DOSE_INT_10	Num	8	Hours since last dose:
212	DOSE_NOTADM_10	Num	8	Reason study drug dose 10 not administered
213	DOSE_NOTADMOTH_10	Char	5000	Other reason study drug dose 10 not administered
214	DOSE_NOTADMSPEC_10	Char	5000	Please give detailed description of why study drug dose 10 was not administered
215	EKG_STUDYYN_3	Num	8	Was an assessment of QTc with EKG or rhythm strip performed 24-48 hours after first administration of study drug?
216	EKG_STUDYDT_3	Num	8	Day of EKG or rhythm strip from which QTc was assessed
217	EKG_STUDYTM_3	Num	8	Time of EKG or rhythm strip from which QTc was assessed
218	EKG_STUDYQTC_3	Num	8	Value for QTc, ms
219	EKG_STUDYNO_3	Num	8	Why was an assessment of QTc not performed 24-48 hours after first administration of study drug?
220	EKG_STUDYNOREAS_3	Char	5000	Describe why assessment of QTc was not performed at 24-48 hours after first dose of study drug
221	IH_YN_2	Num	8	Was the patient located in the study hospital at any time on study day 2 (i.e., admitted, inpatient)?
222	COVID_OOSCALE_2	Num	8	COVID Ordinal Outcomes Scale on Day 2Select the lowest value that occurred on this study day
223	IH_CONTRA_2	Num	8	Contraindicated Medications Day 2Review the electronic health record for orders or administration of the following medications that are considered CONTRAINDICATED:amiodaronechloroquinecimetidinedofetilidephenobarbitalphenytoinsotalol
224	IH_CONTRAOCCUR_2	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a CONTRAINDICATED medication
225	IH_INTERACT_2	Num	8	Medication Interaction Day 2On this study day, review the electronic health record for orders or administration of the following medications that are considered to have a potential interaction with study drug:ampicillinantacidscyclosporinedigoxinflexinide
226	IH_INTERACTOCCUR_2	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a medication with a potential interaction
227	IH_AEASSESS_2	Num	8	Adverse Event Assessment Study Day 2On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
228	IH_AEASSESSREAS_2	Char	5000	Why were AEs not assessed?

Num	Variable	Type	Len	Label
229	IH_SAFEASSESS_2	Num	8	Safety Outcome Assessment Study Day 2 On this study day, study personnel assessed for the occurrence of safety outcomes that might prompt discontinuation of the study drug (and if found recorded in Safety Outcomes CRF).
230	IH_SAFEASSESSREAS_2	Char	5000	Why were safety outcomes not assessed?
231	LABS_YN_2	Num	8	Were the daily labs available for this study day? (Day 2)
232	LABS_NOREAS_2	Char	5000	If no, why? (Day 2)
233	LABS_WBCH_2	Num	8	Highest white blood cell count (/mm ³) (Day 2)
234	LABS_WBCL_2	Num	8	Lowest white blood cell count (/mm ³) (Day 2)
235	LABS_HEMOL_2	Num	8	Lowest hemoglobin (g/dl) (Day 2)
236	LABS_PLATELETL_2	Num	8	Lowest platelet count (/mm ³ ; in thousands) (Day 2)
237	LABS_SODIUMH_2	Num	8	Highest sodium (mEq/L) (Day 2)
238	LABS_SODIUML_2	Num	8	Lowest sodium (mEq/L) (Day 2)
239	LABS_POTASSIUMH_2	Num	8	Highest potassium (mEq/L) (Day 2)
240	LABS_POTASSIUML_2	Num	8	Lowest potassium (mEq/L) (Day 2)
241	LABS_CHLORIDEH_2	Num	8	Highest chloride (mEq/L) (Day 2)
242	LABS_BICARBONATEH_2	Num	8	Highest bicarbonate (mEq/L) (Day 2)
243	LABS_BICARBONATEL_2	Num	8	Lowest bicarbonate (mEq/L) (Day 2)
244	LABS_BUNH_2	Num	8	Highest BUN - Blood Urea Nitrogen (mg/dL) (Day 2)
245	LABS_CREATH_2	Num	8	Highest creatinine (mg/dL) (Day 2)
246	LABS_TROPH_2	Num	8	Highest troponin (mg/dL) (Day 2)
247	LABS_ASTH_2	Num	8	Highest AST - Aspartate aminotransferase (units per liter) (Day 2)
248	LABS_ALTH_2	Num	8	Highest ALT - Alanine aminotransferase (units per liter) (Day 2)
249	LABS_ALPH_2	Num	8	Highest ALP - Alkaline Phosphatase (IU/L) (Day 2)
250	LABS_TOTBILIH_2	Num	8	Highest total bilirubin (mg/dL) (Day 2)
251	LABS_ALBUMINL_2	Num	8	Lowest albumin (g/dL) (Day 2)
252	LABS_PTHH_2	Num	8	Highest PTT - Partial Thromboplastin Time (seconds) (Day 2)
253	LABS_INRH_2	Num	8	Highest INR - International Normalized Ratio (Day 2)
254	EKG_CLINYN_2	Num	8	Was a clinical EKG performed on this study day?
255	EKG_CLINDT_2	Num	8	Day of EKG or rhythm strip from which QTc was assessed
256	EKG_CLINTM_2	Num	8	Time of EKG or rhythm strip from which QTc was assessed
257	EKG_CLINQTC_2	Num	8	Value for QTc, ms
258	IH_YN_3	Num	8	Was the patient located in the study hospital at any time on study day 3 (i.e., admitted, inpatient)?
259	COVID_OOSCALE_3	Num	8	COVID Ordinal Outcomes Scale on Day 3 Select the lowest value that occurred on this study day
260	IH_CONTRA_3	Num	8	Contraindicated Medications Day 3 Review the electronic health record for orders or administration of the following medications that are considered CONTRAINDICATED:amiodaronechloroquinecimetidinedofetilidephenobarbitalphenytoinsotalol
261	IH_CONTRAOCCUR_3	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a CONTRAINDICATED medication

Num	Variable	Type	Len	Label
262	IH_INTERACT_3	Num	8	Medication Interaction Day 2 On this study day, review the electronic health record for orders or administration of the following medications that are considered to have a potential interaction with study drug: ampicillin, antacids, cyclosporine, digoxin, fentanyl, and inhaled beta-agonists.
263	IH_INTERACTOCCUR_3	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a medication with a potential interaction
264	IH_AEASSESS_3	Num	8	Adverse Event Assessment Study Day 3 On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
265	IH_AEASSESSREAS_3	Char	5000	Why were AEs not assessed?
266	IH_SAFEASSESS_3	Num	8	Safety Outcome Assessment Study Day 3 On this study day, study personnel assessed for the occurrence of safety outcomes that might prompt discontinuation of the study drug (and if found recorded in Safety Outcomes CRF).
267	IH_SAFEASSESSREAS_3	Char	5000	Why were safety outcomes not assessed?
268	SOFA_PAO2L_3	Num	8	Lowest PaO2
269	SOFA_PAO2LFIO2_3	Num	8	Value for FiO2 at the time of lowest PaO2 For patients on nasal cannula, use estimation that $FIO_2 = 0.21 + 0.03 * (LPM \text{ of NC O}_2)$
270	SOFA_SPO2L_3	Num	8	Lowest SpO2
271	SOFA_SPO2LFIO2_3	Num	8	Value for FiO2 at the time of lowest SpO2 For patients on nasal cannula, use estimation that $FIO_2 = 0.21 + 0.03 * (LPM \text{ of NC O}_2)$
272	SOFA_PLATL_3	Num	8	Lowest platelet count, per mm ³ (in thousands)
273	SOFA_BILIH_3	Num	8	Highest bilirubin, mg/dL
274	SOFA_GCS_3	Num	8	Lowest Glasgow Coma Scale score
275	SOFA_MAPL_3	Num	8	Lowest mean arterial pressure, mmHg
276	SOFA_VASOYN_3	Num	8	Receipt of vasopressors
277	SOFA_VASO_3__DOBUT	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Dobutamine)
278	SOFA_VASO_3__DOPA	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Dopamine)
279	SOFA_VASO_3__EPI	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Epinephrine)
280	SOFA_VASO_3__NEOSYN	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Neosynephrine)
281	SOFA_VASO_3__NOREPI	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Norepinephrine)
282	SOFA_VASO_3__VASOP	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Vasopressin)
283	SOFA_DOBUT_3	Num	8	Dobutamine dose: (mcg/kg/min)
284	SOFA_DOPA_3	Num	8	Dopamine dose: (mcg/kg/min)
285	SOFA_EPI_3	Num	8	Epinephrine dose: (mcg/kg/min)
286	SOFA_NOREPI_3	Num	8	Norepinephrine dose: (mcg/kg/min)
287	SOFA_NEOSYN_3	Num	8	Neosynephrine dose: (mcg/kg/min)
288	SOFA_VASOP_3	Num	8	Vasopressin dose: (mcg/kg/min)
289	SOFA_CREATH_3	Num	8	Highest creatinine, mg/dL

Num	Variable	Type	Len	Label
290	SOFA_UOUT_3	Num	8	Urine output (estimated)
291	SOFA_INRH_3	Num	8	Highest international normalized ratio (INR)
292	LABS_YN_3	Num	8	Were the daily labs available for this study day? (Day 3)
293	LABS_NOREAS_3	Char	5000	If no, why? (Day 3)
294	LABS_WBCH_3	Num	8	Highest white blood cell count (/mm3) (Day 3)
295	LABS_WBCL_3	Num	8	Lowest white blood cell count (/mm3) (Day 3)
296	LABS_HEMOL_3	Num	8	Lowest hemoglobin (g/dl) (Day 3)
297	LABS_SODIUMH_3	Num	8	Highest sodium (mEq/L) (Day 3)
298	LABS_SODIUML_3	Num	8	Lowest sodium (mEq/L) (Day 3)
299	LABS_POTASSIUMH_3	Num	8	Highest potassium (mEq/L) (Day 3)
300	LABS_POTASSIUML_3	Num	8	Lowest potassium (mEq/L) (Day 3)
301	LABS_CHLORIDEH_3	Num	8	Highest chloride (mEq/L) (Day 3)
302	LABS_BICARBONATEH_3	Num	8	Highest bicarbonate (mEq/L) (Day 3)
303	LABS_BICARBONATEL_3	Num	8	Lowest bicarbonate (mEq/L) (Day 3)
304	LABS_BUNH_3	Num	8	Highest BUN - Blood Urea Nitrogen (mg/dL) (Day 3)
305	LABS_TROPH_3	Num	8	Highest troponin (mg/dL) (Day 3)
306	LABS_ASTH_3	Num	8	Highest AST - Aspartate aminotransferase (units per liter) (Day 3)
307	LABS_ALTH_3	Num	8	Highest ALT - Alanine aminotransferase (units per liter) (Day 3)
308	LABS_ALPH_3	Num	8	Highest ALP - Alkaline Phosphatase (IU/L) (Day 3)
309	LABS_ALBUMINL_3	Num	8	Lowest albumin (g/dL) (Day 3)
310	LABS_PTH_3	Num	8	Highest PTT - Partial Thromboplastin Time (seconds) (Day 3)
311	EKG_CLINYN_3	Num	8	Was a clinical EKG performed on this study day?
312	EKG_CLINOBT_3	Num	8	Were any of the clinically obtained EKGs obtained between 24 and 48 hours after the first administration of the study drug?
313	EKG_CLINDT_3	Num	8	Day of EKG or rhythm strip from which QTc was assessed
314	EKG_CLINTM_3	Num	8	Time of EKG or rhythm strip from which QTc was assessed
315	EKG_CLINQTC_3	Num	8	Value for QTc, ms
316	IH_YN_4	Num	8	Was the patient located in the study hospital at any time on study day 4 (i.e., admitted, inpatient)?
317	COVID_OOSCALE_4	Num	8	COVID Ordinal Outcomes Scale on Day 4 Select the lowest value that occurred on this study day
318	IH_CONTRA_4	Num	8	Contraindicated Medications Day 4 Review the electronic health record for orders or administration of the following medications that are considered CONTRAINDICATED: amiodarone, chloroquine, cimetidine, dofetilide, phenobarbital, phenytoin, sotalol
319	IH_CONTRAOCCUR_4	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a CONTRAINDICATED medication
320	IH_INTERACT_4	Num	8	Medication Interaction Day 4 On this study day, review the electronic health record for orders or administration of the following medications that are considered to have a potential interaction with study drug: ampicillin, antacids, cyclosporine, digoxin, flecainide
321	IH_INTERACTOCCUR_4	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a medication with a potential interaction

Num	Variable	Type	Len	Label
322	IH_AEASSESS_4	Num	8	Adverse Event Assessment Study Day 4 On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
323	IH_AEASSESSREAS_4	Char	5000	Why were AEs not assessed?
324	IH_SAFEASSESS_4	Num	8	Safety Outcome Assessment Study Day 4 On this study day, study personnel assessed for the occurrence of safety outcomes that might prompt discontinuation of the study drug (and if found recorded in Safety Outcomes CRF).
325	IH_SAFEASSESSREAS_4	Char	5000	Why were safety outcomes not assessed?
326	LABS_YN_4	Num	8	Were the daily labs available for this study day? (Day 4)
327	LABS_NOREAS_4	Char	5000	If no, why? (Day 4)
328	LABS_WBCH_4	Num	8	Highest white blood cell count (/mm ³) (Day 4)
329	LABS_WBCL_4	Num	8	Lowest white blood cell count (/mm ³) (Day 4)
330	LABS_HEMOL_4	Num	8	Lowest hemoglobin (g/dl) (Day 4)
331	LABS_PLATELETL_4	Num	8	Lowest platelet count (/mm ³ ; in thousands) (Day 4)
332	LABS_SODIUMH_4	Num	8	Highest sodium (mEq/L) (Day 4)
333	LABS_SODIUML_4	Num	8	Lowest sodium (mEq/L) (Day 4)
334	LABS_POTASSIUMH_4	Num	8	Highest potassium (mEq/L) (Day 4)
335	LABS_POTASSIUML_4	Num	8	Lowest potassium (mEq/L) (Day 4)
336	LABS_CHLORIDEH_4	Num	8	Highest chloride (mEq/L) (Day 4)
337	LABS_BICARBONATEH_4	Num	8	Highest bicarbonate (mEq/L) (Day 4)
338	LABS_BICARBONATEL_4	Num	8	Lowest bicarbonate (mEq/L) (Day 4)
339	LABS_BUNH_4	Num	8	Highest BUN - Blood Urea Nitrogen (Day 4)
340	LABS_CREATH_4	Num	8	Highest creatinine (mg/dL) (Day 4)
341	LABS_TROPH_4	Num	8	Highest troponin (mg/dL) (Day 4)
342	LABS_ASTH_4	Num	8	Highest AST - Aspartate aminotransferase (units per liter) (Day 4)
343	LABS_ALTH_4	Num	8	Highest ALT - Alanine aminotransferase (units per liter) (Day 4)
344	LABS_ALPH_4	Num	8	Highest ALP - Alkaline Phosphatase (IU/L) (Day 4)
345	LABS_TOTBILIH_4	Num	8	Highest total bilirubin (mg/dL) (Day 4)
346	LABS_ALBUMINL_4	Num	8	Lowest albumin (g/dL) (Day 4)
347	LABS_PTHH_4	Num	8	Highest PTT - Partial Thromboplastin Time (seconds) (Day 4)
348	LABS_INRH_4	Num	8	Highest INR - International Normalized Ratio (Day 4)
349	EKG_CLINYN_4	Num	8	Was a clinical EKG performed on this study day?
350	EKG_CLINDT_4	Num	8	Day of EKG or rhythm strip from which QTc was assessed
351	EKG_CLINTM_4	Num	8	Time of EKG or rhythm strip from which QTc was assessed
352	EKG_CLINQTC_4	Num	8	Value for QTc, ms
353	IH_YN_5	Num	8	Was the patient located in the study hospital at any time on study day 5 (i.e., admitted, inpatient)?
354	COVID_OOSCALE_5	Num	8	COVID Ordinal Outcomes Scale on Day 5 Select the lowest value that occurred on this study day

Num	Variable	Type	Len	Label
355	IH_CONTRA_5	Num	8	Contraindicated Medications Day 5 Review the electronic health record for orders or administration of the following medications that are considered CONTRAINDICATED: amiodarone, chloroquine, cimetidine, dofetilide, phenobarbital, phenytoin, sotalol
356	IH_CONTRAOCCUR_5	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a CONTRAINDICATED medication
357	IH_INTERACT_5	Num	8	Medication Interaction Day 5 On this study day, review the electronic health record for orders or administration of the following medications that are considered to have a potential interaction with study drug: ampicillin, antacids, cyclosporine, digoxin, flecainide
358	IH_INTERACTOCCUR_5	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a medication with a potential interaction
359	IH_AEASSESS_5	Num	8	Adverse Event Assessment Study Day 5 On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
360	IH_AEASSESSREAS_5	Char	5000	Why were AEs not assessed?
361	IH_SAFEASSESS_5	Num	8	Safety Outcome Assessment Study Day 5 On this study day, study personnel assessed for the occurrence of safety outcomes that might prompt discontinuation of the study drug (and if found recorded in Safety Outcomes CRF).
362	IH_SAFEASSESSREAS_5	Char	5000	Why were safety outcomes not assessed?
363	LABS_YN_5	Num	8	Were the daily labs available for this study day? (Day 5)
364	LABS_NOREAS_5	Char	5000	If no, why? (Day 5)
365	LABS_WBCH_5	Num	8	Highest white blood cell count (/mm ³) (Day 5)
366	LABS_WBCL_5	Num	8	Lowest white blood cell count (/mm ³) (Day 5)
367	LABS_HEMOL_5	Num	8	Lowest hemoglobin (g/dl) (Day 5)
368	LABS_PLATELETL_5	Num	8	Lowest platelet count (Day 5)
369	LABS_SODIUMH_5	Num	8	Highest sodium (mEq/L) (Day 5)
370	LABS_SODIUML_5	Num	8	Lowest sodium (mEq/L) (Day 5)
371	LABS_POTASSIUMH_5	Num	8	Highest potassium (mEq/L) (Day 5)
372	LABS_POTASSIUML_5	Num	8	Lowest potassium (mEq/L) (Day 5)
373	LABS_CHLORIDEH_5	Num	8	Highest chloride (mEq/L) (Day 5)
374	LABS_BICARBONATEH_5	Num	8	Highest bicarbonate (mEq/L) (Day 5)
375	LABS_BICARBONATEL_5	Num	8	Lowest bicarbonate (mEq/L) (Day 5)
376	LABS_BUNH_5	Num	8	Highest BUN - Blood Urea Nitrogen (mg/dL) (Day 5)
377	LABS_CREATH_5	Num	8	Highest creatinine (mg/dL) (Day 5)
378	LABS_TROPH_5	Num	8	Highest troponin (mg/dL) (Day 5)
379	LABS_ASTH_5	Num	8	Highest AST - Aspartate aminotransferase (units per liter) (Day 5)
380	LABS_ALTH_5	Num	8	Highest ALT - Alanine aminotransferase (units per liter) (Day 5)
381	LABS_ALPH_5	Num	8	Highest ALP - Alkaline Phosphatase (IU/L) (Day 5)
382	LABS_TOTBILIH_5	Num	8	Highest total bilirubin (mg/dL) (Day 5)
383	LABS_ALBUMINL_5	Num	8	Lowest albumin (g/dL) (Day 5)
384	LABS_PTTH_5	Num	8	Highest PTT - Partial Thromboplastin Time (seconds) (Day 5)
385	LABS_INRH_5	Num	8	Highest INR - International Normalized Ratio (Day 5)

Num	Variable	Type	Len	Label
386	EKG_CLINYN_5	Num	8	Was a clinical EKG performed on this study day?
387	EKG_CLINDT_5	Num	8	Day of EKG or rhythm strip from which QTc was assessed
388	EKG_CLINDTM_5	Num	8	Time of EKG or rhythm strip from which QTc was assessed
389	EKG_CLINQTC_5	Num	8	Value for QTc, ms
390	OUT_OOSYN_8	Num	8	Was information on the COVID Ordinal Outcome Scale available at 8 days?
391	OUT_OOSNOSPEC_8	Char	5000	Please describe other reason why
392	OUT_SRC_8	Num	8	Primary source of of day 8 information
393	OUT_SRCSPEC_8	Char	5000	Other source of day 8 information
394	OUT_DT_8	Num	8	Day that 8 day assessment was performed
395	OUT_TM_8	Num	8	Time that 8 day assessment was performed
396	COVID_OOSCALE_8	Num	8	COVID Ordinal Outcomes Scale on Day 8Select the lowest value that occurred on this study day
397	OUT_SYMPYN_8	Num	8	Did the patient report any symptoms on day 8?
398	OUT_SYMP_8__COUGH	Num	8	Which symptoms did the patient report? (choice=Cough)
399	OUT_SYMP_8__CT	Num	8	Which symptoms did the patient report? (choice=Chest tightness)
400	OUT_SYMP_8__FEVER	Num	8	Which symptoms did the patient report? (choice=Fever (temperature > 99.5°F with a thermometer))
401	OUT_SYMP_8__FEVERISH	Num	8	Which symptoms did the patient report? (choice=Feeling feverish)
402	OUT_SYMP_8__OTH	Num	8	Which symptoms did the patient report? (choice=Other)
403	OUT_SYMP_8__SOB	Num	8	Which symptoms did the patient report? (choice=Shortness of breath)
404	OUT_SYMP_8__ST	Num	8	Which symptoms did the patient report? (choice=Sore throat)
405	OUT_SYMP_8__WEAK	Num	8	Which symptoms did the patient report? (choice=Weakness or fatigue)
406	OUT_SYMPOTH_8	Char	5000	Please specify:
407	OUT_AEASSESS_8	Num	8	Adverse Event Assessment Study Day 8On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
408	OUT_AEASSESSREAS_8	Char	5000	Why were AEs not assessed?
409	OUT_SAFEASSESS_8	Num	8	Safety Outcome Assessment Study Day 8On this study day, study personnel assessed for the occurrence of safety outcomes (and if found recorded in Safety Outcomes CRF).
410	OUT_SAFEASSESSREAS_8	Char	5000	Why were safety outcomes not assessed?
411	OUT_OOSYN_15	Num	8	Was information on the COVID Ordinal Outcome Scale available at 15 days?
412	OUT_OOSNOSPEC_15	Char	5000	Please describe other reason why
413	OUT_SRC_15	Num	8	Primary source of of day 15 information
414	OUT_SRCSPEC_15	Char	5000	Other source of day 15 information
415	OUT_DT_15	Num	8	Day that 15 day assessment was performed
416	OUT_TM_15	Num	8	Time that 15 day assessment was performed
417	COVID_OOSCALE_15	Num	8	COVID Ordinal Outcomes Scale on Day 15Select the lowest value that occurred on this study day
418	OUT_SYMPYN_15	Num	8	Did the patient report any symptoms on day 15?
419	OUT_SYMP_15__COUGH	Num	8	Which symptoms did the patient report? (choice=Cough)
420	OUT_SYMP_15__CT	Num	8	Which symptoms did the patient report? (choice=Chest tightness)

Num	Variable	Type	Len	Label
421	OUT_SYMP_15__FEVER	Num	8	Which symptoms did the patient report? (choice=Fever (temperature > 99.5°F with a thermometer))
422	OUT_SYMP_15__FEVERISH	Num	8	Which symptoms did the patient report? (choice=Feeling feverish)
423	OUT_SYMP_15__OTH	Num	8	Which symptoms did the patient report? (choice=Other)
424	OUT_SYMP_15__SOB	Num	8	Which symptoms did the patient report? (choice=Shortness of breath)
425	OUT_SYMP_15__ST	Num	8	Which symptoms did the patient report? (choice=Sore throat)
426	OUT_SYMP_15__WEAK	Num	8	Which symptoms did the patient report? (choice=Weakness or fatigue)
427	OUT_SYMPOTH_15	Char	5000	Please specify:
428	OUT_AEASSESS_15	Num	8	Adverse Event Assessment Study Day 15On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
429	OUT_AEASSESSREAS_15	Char	5000	Why were AEs not assessed?
430	OUT_SAFEASSESS_15	Num	8	Safety Outcome Assessment Study Day 15On this study day, study personnel assessed for the occurrence of safety outcomes (and if found recorded in Safety Outcomes CRF).
431	OUT_SAFEASSESSREAS_15	Char	5000	Why were safety outcomes not assessed?
432	OUT_OOSYN_29	Num	8	Was information on the COVID Ordinal Outcome Scale available at 29 days?
433	OUT_OOSNOSPEC_29	Char	5000	Please describe other reason why
434	OUT_SRC_29	Num	8	Primary source of of day 29 information
435	OUT_SRCSPEC_29	Char	5000	Other source of day 29 information
436	OUT_DT_29	Num	8	Day that 29 day assessment was performed
437	OUT_TM_29	Num	8	Time that 29 day assessment was performed
438	COVID_OOSCALE_29	Num	8	COVID Ordinal Outcomes Scale on Day 29Select the lowest value that occurred on this study day
439	OUT_SYMPYN_29	Num	8	Did the patient report any symptoms on day 29?
440	OUT_SYMP_29__COUGH	Num	8	Which symptoms did the patient report? (choice=Cough)
441	OUT_SYMP_29__CT	Num	8	Which symptoms did the patient report? (choice=Chest tightness)
442	OUT_SYMP_29__FEVER	Num	8	Which symptoms did the patient report? (choice=Fever (temperature > 99.5°F with a thermometer))
443	OUT_SYMP_29__FEVERISH	Num	8	Which symptoms did the patient report? (choice=Feeling feverish)
444	OUT_SYMP_29__OTH	Num	8	Which symptoms did the patient report? (choice=Other)
445	OUT_SYMP_29__SOB	Num	8	Which symptoms did the patient report? (choice=Shortness of breath)
446	OUT_SYMP_29__ST	Num	8	Which symptoms did the patient report? (choice=Sore throat)
447	OUT_SYMP_29__WEAK	Num	8	Which symptoms did the patient report? (choice=Weakness or fatigue)
448	OUT_SYMPOTH_29	Char	5000	Please specify:
449	OUT_AEASSESS_29	Num	8	Adverse Event Assessment Study Day 29On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
450	OUT_AEASSESSREAS_29	Char	5000	Why were AEs not assessed?
451	OUT_SAFEASSESS_29	Num	8	Safety Outcome Assessment Study Day 29On this study day, study personnel assessed for the occurrence of safety outcomes (and if found recorded in Safety Outcomes CRF).
452	OUT_SAFEASSESSREAS_29	Char	5000	Why were safety outcomes not assessed?
453	IHO_COOSPTDISCH	Num	8	Patient discharged home according to COVID OO Scale:

Num	Variable	Type	Len	Label
454	IHO_DISCHYN	Num	8	Was the patient discharged alive from the hospital on or before study day 29?
455	IHO_DISCHDT	Num	8	Hospital Discharge Day
456	IHO_DISCHTM	Num	8	Hospital Discharge Time
457	IHO_DISCHDEST	Num	8	Patient destination at discharge:
458	IHO_CHLOR	Num	8	Did the patient receive chloroquine between randomization and hospital discharge?
459	IHO_CHLORDT	Num	8	Day of first chloroquine dose
460	IHO_CHLORTM	Num	8	Time of first chloroquine dose
461	IHO_HYDROXYCHLOR	Num	8	Did the patient receive open label hydroxychloroquine between randomization and hospital discharge?
462	IHO_HYDROXYCHLORDT	Num	8	Day of first hydroxychloroquine dose
463	IHO_HYDROXYCHLORTM	Num	8	Time of first hydroxychloroquine dose
464	IHO_REMDESIVIR	Num	8	Did the patient receive remdesivir between randomization and hospital discharge?
465	IHO_REMDESIVIRDT	Num	8	Day of first remdesivir dose
466	IHO_REMDESIVIRTM	Num	8	Time of first remdesivir dose
467	IHO_LOPINAVIR	Num	8	Did the patient receive lopinavir/ritonavir between randomization and hospital discharge?
468	IHO_LOPINAVIRDT	Num	8	Day of first lopinavir/ritonavir dose
469	IHO_LOPINAVIRTM	Num	8	Time of first lopinavir/ritonavir dose
470	IHO_AVOTH	Num	8	Did the patient receive any other antiviral between randomization and hospital discharge?
471	IHO_AVOTHSPEC	Char	5000	Name of first other antiviral
472	IHO_AVOTHDT	Num	8	Day of first dose of other antiviral
473	IHO_AVOTHTM	Num	8	Time of first dose of other antiviral
474	IHO_CONPLAS	Num	8	Did the patient receive convalescent plasma between randomization and hospital discharge?
475	IHO_CONPASDT	Num	8	Day patient first received convalescent plasma:
476	IHO_CONPASTM	Num	8	Time patient first received convalescent plasma:
477	IHO_IMMGLOB	Num	8	Did the patient receive SARS-CoV-2 hyperimmune globulin between randomization and hospital discharge?
478	IHO_IMMGLOBDT	Num	8	Day patient first received SARS-CoV-2 hyperimmune globulin:
479	IHO_IMMGLOBTM	Num	8	Time patient first received SARS-CoV-2 hyperimmune globulin:
480	IHO_MONOCANTI	Num	8	Did the patient receive monoclonal antibodies between randomization and hospital discharge?
481	IHO_MONOCANTIDT	Num	8	Day patient first received monoclonal antibodies:
482	IHO_MONOCANTITM	Num	8	Time patient first received monoclonal antibodies:
483	IHO_CORTICOSTER	Num	8	Did the patient receive corticosteroids between randomization and hospital discharge?
484	IHO_CORTICOSTERDT	Num	8	Day of first corticosteroid dose
485	IHO_CORTICOSTERTM	Num	8	Time of first corticosteroid dose

Num	Variable	Type	Len	Label
486	IHO_TOCILIZUMAB	Num	8	Did the patient receive tocilizumab between randomization and hospital discharge?
487	IHO_TOCILIZUMABDT	Num	8	Day of first tocilizumab dose
488	IHO_TOCILIZUMABTM	Num	8	Time of first tocilizumab dose
489	IHO_SARILUMAB	Num	8	Did the patient receive sarilumab between randomization and hospital discharge?
490	IHO_SARILUMABDT	Num	8	Day of first sarilumab dose
491	IHO_SARILUMABTM	Num	8	Time of first sarilumab dose
492	IHO_INTERFERON	Num	8	Did the patient receive Interferon _ between randomization and hospital discharge?
493	IHO_INTERFERONDT	Num	8	Day of first Interferon β dose
494	IHO_INTERFERONTM	Num	8	Time of first Interferon dose
495	IHO_IMMOTH	Num	8	Did the patient receive any other immunomodulating medication between randomization and hospital discharge?
496	IHO_IMMOTHSPEC	Char	5000	Name of other immunomodulating medications
497	IHO_IMMOTHTDT	Num	8	Day of first other immunomodulating medications
498	IHO_IMMOTHTM	Num	8	Time of first other immunomodulating medications
499	IHO_AZITHRO	Num	8	Did the patient receive Azithromycin between randomization and day 8?
500	IHO_AZITHRODT	Num	8	Day of first dose of Azithromycin
501	IHO_AZITHROTM	Num	8	Time of first dose of Azithromycin
502	IHO_ABOTH	Num	8	Did the patient receive any antibiotics (other than azithromycin) between randomization and day 8?
503	IHO_ABOTHTDT	Num	8	Day of first dose of first other antibiotic after randomization
504	IHO_ABOTHTM	Num	8	Time of first dose of first other antibiotic after randomization
505	IHO_COVIDTTYTYPE_1	Num	8	Type of first SARS-CoV-2 test
506	IHO_COVIDTTYPESPEC_1	Char	5000	Other test type (1)
507	IHO_COVIDTSRC_1	Num	8	Source of specimen (1)
508	IHO_COVIDTSRCSPEC_1	Char	5000	Other specimen source (1)
509	IHO_COVIDTODT_1	Num	8	Day collected (1)
510	IHO_COVIDTOTM_1	Num	8	Time collected (1)
511	IHO_COVIDTRDT_1	Num	8	Day resulted (1)
512	IHO_COVIDTRTM_1	Num	8	Time resulted (1)
513	IHO_COVIDTRES_1	Num	8	First SARS-CoV-2 result
514	IHO_COVIDTRESSPEC_1	Char	5000	Other SARS-CoV-2 result (1)
515	IHO_COVIDTYN_2	Num	8	Was an additional SARS-CoV2 test performed?
516	IHO_COVIDTTYTYPE_2	Num	8	Type of second SARS-CoV-2 test
517	IHO_COVIDTTYPESPEC_2	Char	5000	Other test type (2)
518	IHO_COVIDTSRC_2	Num	8	Source of specimen (2)
519	IHO_COVIDTSRCSPEC_2	Char	5000	Other specimen source (2)
520	IHO_COVIDTODT_2	Num	8	Day collected (2)

Num	Variable	Type	Len	Label
521	IHO_COVIDTOTM_2	Num	8	Time collected (2)
522	IHO_COVIDTRDT_2	Num	8	Day resulted (2)
523	IHO_COVIDTRTM_2	Num	8	Time resulted (2)
524	IHO_COVIDTRES_2	Num	8	Second SARS-CoV-2 result
525	IHO_COVIDTRESSPEC_2	Char	5000	Other SARS-CoV-2 result (2)
526	IHO_COVIDTYN_3	Num	8	Was an additional SARS-CoV2 test performed?
527	IHO_COVIDTTYTYPE_3	Num	8	Type of third SARS-CoV-2 test
528	IHO_COVIDTTYYPESPEC_3	Char	5000	Other test type (3)
529	IHO_COVIDTSRC_3	Num	8	Source of specimen (3)
530	IHO_COVIDTSRCSPEC_3	Char	5000	Other specimen source (3)
531	IHO_COVIDTODT_3	Num	8	Day collected (3)
532	IHO_COVIDTOTM_3	Num	8	Time collected (3)
533	IHO_COVIDTRDT_3	Num	8	Day resulted (3)
534	IHO_COVIDTRTM_3	Num	8	Time resulted (3)
535	IHO_COVIDTRES_3	Num	8	Third SARS-CoV-2 result
536	IHO_COVIDTRESSPEC_3	Char	5000	Other SARS-CoV-2 result (3)
537	IHO_COVIDTYN_4	Num	8	Was an additional SARS-CoV2 test performed?
538	IHO_COVIDTTYTYPE_4	Num	8	Type of fourth SARS-CoV-2 test
539	IHO_COVIDTTYYPESPEC_4	Char	5000	Other test type (4)
540	IHO_COVIDTSRC_4	Num	8	Source of specimen (4)
541	IHO_COVIDTSRCSPEC_4	Char	5000	Other specimen source (4)
542	IHO_COVIDTODT_4	Num	8	Day collected (4)
543	IHO_COVIDTOTM_4	Num	8	Time collected (4)
544	IHO_COVIDTRDT_4	Num	8	Day resulted (4)
545	IHO_COVIDTRTM_4	Num	8	Time resulted (4)
546	IHO_COVIDTRES_4	Num	8	Fourth SARS-CoV-2 result
547	IHO_COVIDTRESSPEC_4	Char	5000	Other SARS-CoV-2 result (4)
548	IHO_BCULTYN	Num	8	Were any blood cultures drawn between hospital presentation and study day 7 positive?
549	IHO_BCULTDT	Num	8	Day first positive blood culture collected:
550	IHO_BCULTTM	Num	8	Time first positive blood culture collected:
551	IHO_BCULTORG__1	Num	8	Organisms identified in first positive blood culture (choice=Acinetobacter baumannii)
552	IHO_BCULTORG__10	Num	8	Organisms identified in first positive blood culture (choice=Lactobacillus)
553	IHO_BCULTORG__11	Num	8	Organisms identified in first positive blood culture (choice=Micrococcus)
554	IHO_BCULTORG__12	Num	8	Organisms identified in first positive blood culture (choice=Proteus mirabilis)
555	IHO_BCULTORG__13	Num	8	Organisms identified in first positive blood culture (choice=Pseudomonas aeruginosa)
556	IHO_BCULTORG__14	Num	8	Organisms identified in first positive blood culture (choice=Serratia marcescens)

Num	Variable	Type	Len	Label
557	IHO_BCULTORG__15	Num	8	Organisms identified in first positive blood culture (choice=Staphylococcus aureus)
558	IHO_BCULTORG__16	Num	8	Organisms identified in first positive blood culture (choice=Stenotrophomonas maltophilia)
559	IHO_BCULTORG__17	Num	8	Organisms identified in first positive blood culture (choice=Streptococcus pneumoniae)
560	IHO_BCULTORG__18	Num	8	Organisms identified in first positive blood culture (choice=Viridans group streptococci)
561	IHO_BCULTORG__19	Num	8	Organisms identified in first positive blood culture (choice=Other)
562	IHO_BCULTORG__2	Num	8	Organisms identified in first positive blood culture (choice=Bacillus)
563	IHO_BCULTORG__3	Num	8	Organisms identified in first positive blood culture (choice=beta-hemolytic streptococci)
564	IHO_BCULTORG__4	Num	8	Organisms identified in first positive blood culture (choice=Coagulase-negative staphylococci)
565	IHO_BCULTORG__5	Num	8	Organisms identified in first positive blood culture (choice=Corynebacterium)
566	IHO_BCULTORG__6	Num	8	Organisms identified in first positive blood culture (choice=Enterobacter cloacae)
567	IHO_BCULTORG__7	Num	8	Organisms identified in first positive blood culture (choice=Enterococcus)
568	IHO_BCULTORG__8	Num	8	Organisms identified in first positive blood culture (choice=Escheria coli)
569	IHO_BCULTORG__9	Num	8	Organisms identified in first positive blood culture (choice=Klebsiella pneumoniae)
570	IHO_BCULTORGSPEC	Char	5000	Other organisms identified in first positive blood culture
571	IHO_RCULTYN	Num	8	Were any bacterial respiratory cultures (sputum, tracheal aspirate, or bronchoalveolar lavage) obtained between hospital presentation and study day 7 positive?
572	IHO_RCULTDT	Num	8	Day first positive culture collected:
573	IHO_RCULTTM	Num	8	Time first positive culture collected:
574	IHO_RCULTSRC	Num	8	Source of Culture
575	IHO_RCULTORG__1	Num	8	Organisms identified in first positive respiratory culture: (choice=Acinetobacter baumannii)
576	IHO_RCULTORG__10	Num	8	Organisms identified in first positive respiratory culture: (choice=Lactobacillus)
577	IHO_RCULTORG__11	Num	8	Organisms identified in first positive respiratory culture: (choice=Micrococcus)
578	IHO_RCULTORG__12	Num	8	Organisms identified in first positive respiratory culture: (choice=Proteus mirabilis)
579	IHO_RCULTORG__13	Num	8	Organisms identified in first positive respiratory culture: (choice=Pseudomonas aeruginosa)
580	IHO_RCULTORG__14	Num	8	Organisms identified in first positive respiratory culture: (choice=Serratia marcescens)
581	IHO_RCULTORG__15	Num	8	Organisms identified in first positive respiratory culture: (choice=Staphylococcus aureus)
582	IHO_RCULTORG__16	Num	8	Organisms identified in first positive respiratory culture: (choice=Stenotrophomonas maltophilia)
583	IHO_RCULTORG__17	Num	8	Organisms identified in first positive respiratory culture: (choice=Streptococcus pneumoniae)

Num	Variable	Type	Len	Label
584	IHO_RCULTORG__18	Num	8	Organisms identified in first positive respiratory culture: (choice=Viridans group streptococci)
585	IHO_RCULTORG__19	Num	8	Organisms identified in first positive respiratory culture: (choice=Other)
586	IHO_RCULTORG__2	Num	8	Organisms identified in first positive respiratory culture: (choice=Bacillus)
587	IHO_RCULTORG__3	Num	8	Organisms identified in first positive respiratory culture: (choice=beta-hemolytic streptococci)
588	IHO_RCULTORG__4	Num	8	Organisms identified in first positive respiratory culture: (choice=Coagulase-negative staphylococci)
589	IHO_RCULTORG__5	Num	8	Organisms identified in first positive respiratory culture: (choice=Corynebacterium)
590	IHO_RCULTORG__6	Num	8	Organisms identified in first positive respiratory culture: (choice=Enterobacter cloacae)
591	IHO_RCULTORG__7	Num	8	Organisms identified in first positive respiratory culture: (choice=Enterococcus)
592	IHO_RCULTORG__8	Num	8	Organisms identified in first positive respiratory culture: (choice=Escheria coli)
593	IHO_RCULTORG__9	Num	8	Organisms identified in first positive respiratory culture: (choice=Klebsiella pneumoniae)
594	IHO_VIRINFYN	Num	8	Was another acute viral infection identified by clinical testing OTHER THAN SARS-CoV-2?
595	IHO_ADENOVIR	Num	8	Other acute viral infection: Adenovirus
596	IHO_ADENOVIRSRC	Num	8	Adenovirus specimen source
597	IHO_ENTEROVIR	Num	8	Other acute viral infection: Enterovirus
598	IHO_ENTEROVIRSRC	Num	8	Enterovirus specimen source
599	IHO_CORONAVIROTH	Num	8	Other acute viral infection: Coronavirus OC43, NL63, 229E, and HKU1
600	IHO_CORONAVIROTHSRC	Num	8	Coronavirus OC43, NL63, 229E, and HKU1 specimen source
601	IHO_METAPNEUMOVIR	Num	8	Other acute viral infection: Human metapneumovirus
602	IHO_METAPNEUMOVIRSRC	Num	8	Human metapneumovirus specimen source
603	IHO_FLUA	Num	8	Other acute viral infection: Influenza A
604	IHO_FLUASRC	Num	8	Influenza A specimen source
605	IHO_FLUB	Num	8	Other acute viral infection: Influenza B
606	IHO_FLUBSRC	Num	8	Influenza B specimen source
607	IHO_PARAFLU	Num	8	Other acute viral infection: Parainfluenza
608	IHO_PARAFLUSRC	Num	8	Parainfluenza specimen source
609	IHO_RHINOVIR	Num	8	Other acute viral infection: Rhinovirus
610	IHO_RHINOVIRSRC	Num	8	Rhinovirus specimen source
611	IHO_RSV	Num	8	Other acute viral infection: Respiratory Syncytial Virus
612	IHO_RSVSRC	Num	8	Respiratory Syncytial Virus specimen source
613	IHO_DVT	Num	8	Was the patient diagnosed with a deep venous thrombosis (DVT) between randomization and the first of discharge, death, or study day 29?
614	IHO_DVTD	Num	8	Day of first study demonstrating DVT:
615	IHO_DVTTM	Num	8	Time of first study demonstrating DVT:

Num	Variable	Type	Len	Label
616	IHO_PE	Num	8	Was the patient diagnosed with a pulmonary embolism (PE) between randomization and the first of discharge, death, or study day 29?
617	IHO_PEDT	Num	8	Day of first study demonstrating PE:
618	IHO_PETM	Num	8	Time of first study demonstrating PE:
619	IHO_OXY	Num	8	Did the patient receive oxygen between randomization and the first of discharge, death, or study day 29? Supplemental oxygen is defined as oxygen administered by nasal cannula, face mask, high-flow nasal cannula, non-invasive ventilation, or invasive vent
620	IHO_OXYDT	Num	8	Day oxygen first received
621	IHO_OXYTM	Num	8	Time oxygen first received
622	IHO_OXYDISCON	Num	8	Was the patient still receiving oxygen at the first of discharge, death, or study day 29?
623	IHO_OXYDISCONDT	Num	8	Day of final discontinuation of oxygen
624	IHO_OXYDISCONTM	Num	8	Time of final discontinuation of oxygen
625	IHO_HFNC	Num	8	Did the patient receive high flow nasal cannula between randomization and the first of discharge, death, or study day 29? High flow nasal cannula refers to devices that deliver oxygen at 30 to 60 liters per minute with a titratable FiO ₂ . Brand names include
626	IHO_HFNCDT	Num	8	Day high flow nasal cannula first received
627	IHO_HFNCTM	Num	8	Time high flow nasal cannula first received
628	IHO_HFNCDISCON	Num	8	Was the patient still receiving high flow nasal cannula at the first of discharge, death, or study day 29?
629	IHO_HFNCDISCONDT	Num	8	Day of final discontinuation of high flow nasal cannula
630	IHO_HFNCDISCONTM	Num	8	Time of final discontinuation of high flow nasal cannula
631	IHO_NIV	Num	8	Did the patient receive non-invasive ventilation (bipap) between randomization and the first of discharge, death, or study day 29?
632	IHO_NIVDT	Num	8	Day non-invasive ventilation first received
633	IHO_NIVTM	Num	8	Time non-invasive ventilation first received
634	IHO_NIVDISCON	Num	8	Was the patient still receiving non-invasive ventilation at the first of discharge, death, or study day 29?
635	IHO_NIVDISCONDT	Num	8	Day of final discontinuation
636	IHO_NIVDISCONTM	Num	8	Time of final discontinuation
637	IHO_IMV	Num	8	Did the patient receive invasive mechanical ventilation between randomization and the first of discharge, death, or study day 29? Invasive mechanical ventilation refers to ventilation via endotracheal tube or tracheostomy
638	IHO_IMVDT	Num	8	Day invasive mechanical ventilation received
639	IHO_IMVTM	Num	8	Time invasive mechanical ventilation received
640	IHO_IMVDISCON	Num	8	Was the patient still receiving invasive mechanical ventilation at the first of discharge, death or study day 29?
641	IHO_IMVDISCONDT	Num	8	Day of final discontinuation of invasive mechanical ventilation
642	IHO_IMVDISCONTM	Num	8	Time of final discontinuation of invasive mechanical ventilation
643	IHO_ECMO	Num	8	Did the patient receive extracorporeal membrane oxygenation (ECMO) between randomization and the first of discharge, death, or study day 29?
644	IHO_ECMODT	Num	8	Day ECMO first received

Num	Variable	Type	Len	Label
645	IHO_ECMOTM	Num	8	Time ECMO first received
646	IHO_ECMODISCON	Num	8	Was the patient still receiving ECMO at the first of discharge, death, or study day 29?
647	IHO_ECMODISCONDT	Num	8	Day of final discontinuation of ECMO
648	IHO_ECMODISCONTM	Num	8	Time of final discontinuation of ECMO
649	IHO_VASOP	Num	8	Did the patient receive intravenous vasopressors or inotropes between randomization and the first of discharge, death, or study day 29?
650	IHO_VASOPTYPE__1	Num	8	Check all vasopressors and inotropes the patient received (choice=Norepinephrine)
651	IHO_VASOPTYPE__2	Num	8	Check all vasopressors and inotropes the patient received (choice=Epinephrine)
652	IHO_VASOPTYPE__3	Num	8	Check all vasopressors and inotropes the patient received (choice=Vasopressin)
653	IHO_VASOPTYPE__4	Num	8	Check all vasopressors and inotropes the patient received (choice=Phenylephrine)
654	IHO_VASOPTYPE__5	Num	8	Check all vasopressors and inotropes the patient received (choice=Angiotensin II)
655	IHO_VASOPTYPE__6	Num	8	Check all vasopressors and inotropes the patient received (choice=Dobutamine)
656	IHO_VASOPTYPE__7	Num	8	Check all vasopressors and inotropes the patient received (choice=Dopamine)
657	IHO_VASOPTYPE__8	Num	8	Check all vasopressors and inotropes the patient received (choice=Milrinone)
658	IHO_VASOPDT	Num	8	Day of first receipt of vasopressors
659	IHO_VASOPTM	Num	8	Time of first receipt of vasopressors
660	IHO_VASOPDISCON	Num	8	Was the patient still receiving vasopressors at the first of discharge, death, or study day 29?
661	IHO_VASOPDISCONDT	Num	8	Day of final discontinuation of vasopressors/inotropes
662	IHO_VASOPDISCONTM	Num	8	Time of final discontinuation of vasopressors/inotropes
663	IHO_ICU	Num	8	Was the patient ever located in an ICU between randomization and the first of discharge, death, or study day 29?
664	IHO_ICUDT	Num	8	Day of ICU admission
665	IHO_ICUTM	Num	8	Time of ICU admission
666	IHO_ICUDISCH	Num	8	Was patient located in an ICU at the first of discharge, death, or study day 29?
667	IHO_ICUDISCHDT	Num	8	Day of final ICU discharge
668	IHO_ICUDISCHTM	Num	8	Time of final ICU discharge
669	SAFE_SEIZURE	Num	8	Did the patient experience seizures between randomization and day 29?
670	SAFE_SEIZURED	Num	8	Day of first seizure
671	SAFE_ATACH	Num	8	Did the patient experience atrial tachyarrhythmia between randomization and day 29?
672	SAFE_ATACHDT	Num	8	Day of first atrial tachyarrhythmia
673	SAFE_VTACH	Num	8	Did the patient experience ventricular tachyarrhythmia between randomization and day 29?
674	SAFE_VTACHDT	Num	8	Day of first ventricular tachyarrhythmia
675	SAFE_VTACHSPEC	Char	5000	Provide a summary of the type of ventricular tachycardia (e.g. specific mention of monomorphic or polymorphic ventricular tachycardia or torsades de points in the record), the outcome of event (e.g. did the event require chemical or electrical cardioversion)

Num	Variable	Type	Len	Label
676	SAFE_CA	Num	8	Did the patient experience cardiac arrest between randomization and day 29?
677	SAFE_CADT	Num	8	Day of first cardiac arrest
678	SAFE_CASPEC	Char	5000	Provide a summary of the clinical situation leading to cardiac arrest and the outcome of the cardiac arrest. Use only deidentified information (i.e. do not provide medical record number or date of birth, and provide study days instead of exact dates).
679	SAFE_ASTALT	Num	8	Did the patient have an aspartate aminotransferase or alanine aminotransferase elevated to at least twice the local upper limit of normal between randomization and day 29?
680	SAFE_ASTALTDT	Num	8	Day of first elevation of AST or ALT at least twice the local upper limit of normal
681	SAFE_PANCR	Num	8	Did the patient have acute pancreatitis (defined by a clinically obtained lipase level above the local upper limit of normal) between randomization and day 29?
682	SAFE_PANCRDT	Num	8	Day of first meeting criteria for acute pancreatitis
683	SAFE_AKI	Num	8	Did the patient have stage II or greater acute kidney injury by KDIGO Criteria between randomization and day 29? Defined as any of the following: Creatinine 2.0-2.9 times baseline Increase in serum creatinine above 4.0 mg/dl Urine output less than 0.5 ml/kg/h
684	SAFE_AKIDT	Num	8	Day of first meeting criteria for stage II AKI
685	SAFE_RRTNEW	Num	8	Did the patient receive new renal replacement therapy between randomization and day 29?
686	SAFE_RRTNEWDT	Num	8	Day of first receiving RRT
687	SAFE_HYPOGLY	Num	8	Did the patient experience symptomatic hypoglycemia between randomization and day 29?
688	SAFE_HYPOGLYDT	Num	8	Day of first hypoglycemic episode
689	SAFE_NEUTROP	Num	8	Did the patient experience absolute neutrophil count < 1000 (cells/mm3) between randomization and day 29?
690	SAFE_NEUTROPDT	Num	8	What was the first day on which the patient experienced neutropenia?
691	SAFE_LYMPHO	Num	8	Did the patient experience absolute lymphocyte count < 1000 (cells/mm3) between randomization and day 29?
692	SAFE_LYMPHODT	Num	8	What was the first day on which the patient experienced lymphocytopenia?
693	SAFE_ANEMIA	Num	8	Did the patient experience hemoglobin < 12.0 g/dL between randomization and day 29?
694	SAFE_ANEMIADT	Num	8	What was the first day on which the patient experienced anemia?
695	SAFE_THOMBO	Num	8	Did the patient experience a platelet count < 50 (cell/mm3; in thousands) between randomization and day 29?
696	SAFE_THOMBODT	Num	8	What was the first day on which the patient experienced thrombocytopenia?
697	SAFE_DERM	Num	8	Did the patient experience a severe dermatologic reaction between randomization and day 29?
698	SAFE_DERMDT	Num	8	Day dermatologic reaction was first noted?
699	IMG_PRERAND	Num	8	Was any chest imaging available in the 48 hours prior to randomization?
700	IMG_PRERANDTYPE__1	Num	8	Type of chest imaging reviewed (choice=Chest radiograph (X-ray))
701	IMG_PRERANDTYPE__2	Num	8	Type of chest imaging reviewed (choice=Computed Tomography (CT Chest))
702	IMG_PRERANDTYPE__3	Num	8	Type of chest imaging reviewed (choice=Other)

Num	Variable	Type	Len	Label
703	IMG_PRERANDTYPESPEC	Char	5000	Describe other type(s) of chest imaging that was obtained
704	IMG_BLARDS	Num	8	Using all available imaging, was the patient noted to have bilateral opacities/infiltrates that were not fully explained by effusions, lobar/lung collapse, nodules, cardiac failure or fluid overload prior to randomization?
705	IMG_BLARDSCLIN	Num	8	Did patient meet clinical criteria for ARDS at the time of randomization?(< 1 week of symptoms, not explained by cardiac failure, and P/F ratio < 300 or equivalent S/F ratio)
706	IMG_IH	Num	8	Was any chest imaging available between randomization and day 8?
707	IMG_IHTYPE__1	Num	8	Type of chest imaging reviewed (choice=Chest radiograph (X-ray))
708	IMG_IHTYPE__2	Num	8	Type of chest imaging reviewed (choice=Computed Tomography (CT Chest))
709	IMG_IHTYPE__3	Num	8	Type of chest imaging reviewed (choice=Other)
710	IMG_IHTYPESPEC	Char	5000	Describe other type(s) of chest imaging that was obtained
711	IMG_IHARDS	Num	8	Using all available imaging, was the patient noted to have bilateral opacities/infiltrates that were not fully explained by effusions, lobar/lung collapse, nodules, cardiac failure or fluid overload between randomization and day 8?
712	IMG_IHARDSCLIN	Num	8	Did patient meet clinical criteria for ARDS between randomization and day 8?(< 1 week of symptoms, not explained by cardiac failure, and P/F ratio < 300 or equivalent S/F ratio)
713	IMG_ARSDST	Num	8	Day patient first documented as having bilateral opacities/infiltrates:
714	PDO_READM	Num	8	Did the patient experience hospital readmission between discharge from the initial hospitalization and 29 days after randomization?
715	PDO_READMDT	Num	8	Day of first readmission:
716	PDO_ED	Num	8	Did the patient visit an emergency department between discharge from the initial hospitalization and 29 days after randomization?
717	PDO_EDDT	Num	8	Day of first emergency department visit:
718	PDO_OXY	Num	8	Did the patient receive supplemental oxygen between discharge from the initial hospitalization and 29 days after randomization? Supplemental oxygen is defined as oxygen administered by nasal cannula, face mask, high-flow nasal cannula, non-invasive ventil
719	PDO_OXYSTARTDT	Num	8	What was the first day on which the patient received oxygen following discharge from the index hospitalization?
720	PDO_OXYSTILL	Num	8	Is the patient still on oxygen at day 29?
721	PDO_OXYDT	Num	8	<u><I>FINAL</I></u> Day receiving oxygen between discharge and day 29:
722	VS_DT	Num	8	Day this form was completed
723	VS_DIED	Num	8	Did the patient die between randomization and study day 29?
724	VS_DEATHDT	Num	8	Day of death
725	VS_DEATHHOSP	Num	8	Did the patient die prior to hospital discharge?
726	VS_ALIVEDT	Num	8	Last day known to be alive
727	AE_ID	Char	5000	AE identifier
728	AE_DT	Num	8	Day of adverse event:
729	AE_TM	Num	8	Time of adverse event:
730	AE_USERTERM	Char	500	COSTART term: [lookup tool]

Num	Variable	Type	Len	Label
731	AE_DESC	Char	5000	Description of adverse event:
732	AE_SERIOUS	Num	8	Was the adverse event serious?
733	AE_RELDRUG	Num	8	Was the adverse event related to study drug?
734	AE_UNEXPECTED	Num	8	Was the adverse event unexpected (not listed in the investigator brochure or protocol)?
735	AE_STATUS	Num	8	What was the status of the adverse event at the time of the initial AE report?
736	AE_OUTCOME	Num	8	What was the final outcome of the adverse event?
737	AE_RECDDT	Num	8	Day of recovery:
738	PD_DEVDT	Num	8	Day deviation occurred:
739	PD_DEVREPDT	Num	8	Day deviation discovered:
740	PD_DEVTYPE	Num	8	Type of deviation:
741	PD_DRUGTYPE	Num	8	Type of drug error:
742	PD_OTHER	Char	5000	Please specify:
743	PD_DESC	Char	5000	Describe the deviation:
744	PD_RESOLUTION	Char	5000	Describe steps taken to resolve the deviation and prevent future occurrences:
745	PD_DRUGSTOP	Num	8	Was study drug temporarily or permanently discontinued as a result of this deviation?
746	PD_AE	Num	8	Was an adverse event reported as a result of this deviation?
747	WD_YN	Num	8	Did patient withdraw from the study?
748	WD_DT	Num	8	Day withdrawn:
749	WD_TM	Num	8	Time withdrawn:
750	WD_REAS	Num	8	Reason for patient withdrawal
751	WD_REASSPEC	Char	5000	Other reason for patient withdrawal
752	WD_REAS_V2	Num	8	Type of study withdrawal:
753	WD_DETAILS	Char	5000	Details:

Data Set Name: derived_vars.sas7bdat

Num	Variable	Type	Len	Label
1	SUBJECT_ID	Char	9	Subject ID
2	INTERVALNAME	Char	27	Enrollment record or Day 3 Assessment?
3	RAND_DT	Num	8	Randomization day
4	RAND_TM	Num	8	Randomization time
5	VS_DEATHDT	Num	8	Day of death
6	EXTRACT_DT	Num	8	Extract day
7	RAND_TRT	Num	8	Treatment arm
8	D_BL_ICU	Num	8	Baseline ICU
9	D_BMI	Num	8	BMI
10	D_COVID2	Num	8	COVID Ordinal Outcomes Scale on Day 2 (derived)
11	D_COVID3	Num	8	COVID Ordinal Outcomes Scale on Day 3 (derived)
12	D_COVID4	Num	8	COVID Ordinal Outcomes Scale on Day 4 (derived)
13	D_COVID5	Num	8	COVID Ordinal Outcomes Scale on Day 5 (derived)
14	D_COVID8	Num	8	COVID Ordinal Outcomes Scale on Day 8 (derived)
15	D_COVID15	Num	8	COVID Ordinal Outcomes Scale on Day 15 (derived)
16	D_COVID29	Num	8	COVID Ordinal Outcomes Scale on Day 29 (derived)
17	D_MORT15	Num	8	Day 15 mortality
18	D_MORT29	Num	8	Day 29 mortality
19	D_FU_DAYS	Num	8	Follow-Up Days
20	D_DOSES	Num	8	Number of Doses Administered
21	D_ECMO_DEATH	Num	8	Ecmo or Death
22	D_HOSPFREEDAYS	Num	8	Hospital Free Days
23	D_ICUFREEDAYS	Num	8	ICU Free Days
24	D_LASTALIVEDT	Num	8	Last alive day
25	D_ONSET_DURATION	Num	8	Duration of symptoms prior to randomization (days)
26	D_OXYFREEDAYS	Num	8	Oxygen free days
27	D_RACE	Char	80	Race
28	D_REMD_EVER	Num	8	Remdesivir (ever/never)
29	D_PFRATIO	Num	8	P/F ratio
30	D_SFRATIO	Num	8	S/F ratio
31	D_SOFA_NERVOUS	Num	8	SOFA Nervous System
32	D_SOFA_COAG	Num	8	SOFA Coagulation
33	D_SOFA_LIVER	Num	8	SOFA Liver
34	D_SOFA_RENAL	Num	8	SOFA Renal
35	D_SOFA_CARDIO	Num	8	SOFA Cardiovascular
36	D_SOFA_RESP	Num	8	SOFA Respiratory

Num	Variable	Type	Len	Label
37	D_SOFA_GCS	Num	8	Total SOFA (with GCS)
38	D_SOFA_NOGCS	Num	8	Total SOFA (without GCS)
39	D_TIME_TO_RECOVERY	Num	8	Time to recovery
40	D_VASOFREEDAYS	Num	8	Vasopressor Free Days
41	D_VENTFREEDAYS	Num	8	Ventilator Free Days
42	D_DEATHDAY	Num	8	Death day
43	D_MALE_SEX	Char	3	Sex: Male
44	D_BSTATUS_SP02	Char	3	On supplemental oxygen at baseline
45	D_BSTATUS_NO02	Char	3	Not on oxygen baseline
46	D_BL_AGE_S	Num	8	Standardized age at baseline
47	D_SOFA_GCS_S	Num	8	Standardized Total SOFA with GCS at baseline